Atossa Therapeutics, Inc.
NASDAQ Capital MarketTotal Valuation
Atossa Therapeutics, Inc. carries a market capitalization of 25.14M, placing it among publicly traded companies globally. Its enterprise value stands at -6.83M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 25.14M |
| Enterprise Value | -6.83M |
Share Statistics
Atossa Therapeutics, Inc. currently has 9.98M shares outstanding.
| Shares Outstanding | 9.98M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | 0.72 |
| P/TBV Ratio | 0.72 |
| P/FCF Ratio | -0.47 |
| P/OCF Ratio | -0.47 |
Financial Position
Atossa Therapeutics, Inc. maintains a current ratio of 5.69, meaning it holds 5.7x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 5.69 |
| Quick Ratio | 4.79 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -89.23 |
| Return on Assets (ROA) | -77.91 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Atossa Therapeutics, Inc.'s stock has declined approximately -78.21953% over the past 52 weeks. The 50-day moving average sits at 2.38, while the 200-day moving average is 5.63.
| Beta (5Y) | N/A |
| 52-Week Price Change | -78.21953% |
| 50-Day Moving Average | 2.38 |
| 200-Day Moving Average | 5.63 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -39.23M, while operating income came in at -39.25M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -39.25M |
| Pretax Income | -37.71M |
| Net Income | -37.71M |
| EBITDA | -39.23M |
| EBIT | -39.25M |
| Earnings Per Share (EPS) | -4.33 |
Balance Sheet
Total book value stands at 26.83M, with working capital of 25.56M providing operational flexibility.
| Cash & Cash Equivalents | 26.09M |
| Total Debt | N/A |
| Net Debt | -26.09M |
| Equity (Book Value) | 26.83M |
| Book Value Per Share | 2.69 |
| Working Capital | 25.56M |
Cash Flow
Atossa Therapeutics, Inc. produced -35.77M in operating cash flow over the past twelve months. After subtracting -14,000.00 in capital expenditures, free cash flow totaled -35.78M - equivalent to -4.11 per share.
| Operating Cash Flow | -35.77M |
| Capital Expenditures | -14,000.00 |
| Free Cash Flow | -35.78M |
| FCF Per Share | -4.11 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -20.87 |
| FCF Yield | -212.60 |
Stock Splits
Atossa Therapeutics, Inc.'s most recent stock split took place on February 2, 2026 with a 15:1 split ratio.
| Last Split Date | 2/2/2026 |
| Split Ratio | 15:1 |
Scores
Atossa Therapeutics, Inc. posts an Altman Z-Score of -12.42, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -12.42 |